NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$63.21

+1.89 (+3.08%)

(As of 06/5/2023 ET)

Compare

Today's Range: $60.76
▼
$63.26
50-Day Range: $54.15
▼
$66.44
52-Week Range: $42.01
▼
$66.56

Volume: 472,038 shs
Average Volume: 623,634 shs
Market Capitalization: $6.06 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.45

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 3.2% Downside
$61.17 Price Target
Short Interest: Bearish
3.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 0.54
Based on 10 Articles This Week
Insider Trading: Selling Shares
$5.83 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.32) to ($1.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

232nd out of 985 stocks

Pharmaceutical Preparations Industry

109th out of 483 stocks

2.4

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $61.17, Intra-Cellular Therapies has a forecasted downside of 3.2% from its current price of $63.21.
Amount of Analyst Coverage
Intra-Cellular Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
3.71% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently increased by 21.92%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

2.0

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,831,627.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
86.95% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.32) to ($1.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 9.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

June 5, 2023 | finance.yahoo.com

ITCI Jul 2023 65.000 call

June 5, 2023 | msn.com

JP Morgan Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

June 6, 2023 | Edge On The Street (Ad)

ChatGPT Is Already "Old School"

As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.

June 5, 2023 | markets.businessinsider.com

Analyst Expectations for Intra-Cellular Therapies's Future

June 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 28, 2023 | americanbankingnews.com

Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45

June 6, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

May 17, 2023 | americanbankingnews.com

Head to Head Analysis: Intra-Cellular Therapies (NASDAQ:ITCI) and Arbutus Biopharma (NASDAQ:ABUS)

May 8, 2023 | msn.com

Mizuho Maintains Intra-Cellular Therapies (ITCI) Buy Recommendation

May 8, 2023 | finance.yahoo.com

Investing in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gain

May 8, 2023 | americanbankingnews.com

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $76.00

May 8, 2023 | americanbankingnews.com

Cantor Fitzgerald Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $90.00

May 5, 2023 | msn.com

Cantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendation

May 5, 2023 | msn.com

RBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform Recommendation

May 4, 2023 | finance.yahoo.com

‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protection

May 4, 2023 | finanznachrichten.de

Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023 | msn.com

Recap: Intra-Cellular Therapies Q1 Earnings

May 4, 2023 | msn.com

Intra-Cellular Therapies Q1 2023 Earnings Preview

May 4, 2023 | finance.yahoo.com

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023 | americanbankingnews.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $74.00 Average Price Target from Analysts

April 26, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

April 25, 2023 | americanbankingnews.com

SVB Leerink Comments on Intra-Cellular Therapies, Inc.'s FY2027 Earnings (NASDAQ:ITCI)

April 22, 2023 | americanbankingnews.com

Morgan Stanley Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)

April 22, 2023 | americanbankingnews.com

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Sells $630,000.00 in Stock

April 21, 2023 | msn.com

Morgan Stanley Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendation

See More Headlines

ITCI Price History

30 days | 90 days | 365 days | Advanced Chart

ITCI Company Calendar

Last Earnings: 5/04/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 512
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $74.82
High Stock Price Forecast: $98.00
Low Stock Price Forecast: $49.00
Forecasted Upside/Downside: +17.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-256,260,000.00
Net Margins: -73.46%
Pretax Margin: -73.46%
Return on Equity: -33.92%
Return on Assets: -29.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.87
Quick Ratio: 8.52

Sales & Book Value

Annual Sales: $250.31 million
Price / Sales: 24.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.93 per share
Price / Book: 9.12

Miscellaneous

Outstanding Shares: 95,930,000
Free Float: 92,665,000
Market Cap: $6.06 billion
Optionable: Optionable
Beta: 1.13

Key Executives

Sharon Mates
Chairman, President & Chief Executive Officer

Lawrence J. Hineline
Chief Financial Officer, Treasurer & SVP-Finance

Robert E. Davis
Chief Scientific Officer & Senior Vice President

Suresh Durgam
Chief Medical Officer & Senior Vice President

Karen Patruno Sheehy
Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price forecast for 2023?: 10 analysts have issued 12 month price targets for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they predict the company's stock price to reach $74.82 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2023?: Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI shares have increased by 19.4% and is now trading at $63.21.
View the best growth stocks for 2023 here.
Are investors shorting Intra-Cellular Therapies?: Intra-Cellular Therapies saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,560,000 shares, an increase of 21.9% from the April 30th total of 2,920,000 shares. Based on an average daily trading volume, of 893,600 shares, the days-to-cover ratio is currently 4.0 days.
View Intra-Cellular Therapies' Short Interest.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.17. The biopharmaceutical company had revenue of $95.31 million for the quarter, compared to analysts' expectations of $92.14 million. Intra-Cellular Therapies had a negative net margin of 73.46% and a negative trailing twelve-month return on equity of 33.92%.
What ETFs hold Intra-Cellular Therapies' stock?: ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Psychedelics ETF (PSIL), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Innovator IBD Breakout Opportunities ETF (BOUT) and Principal Healthcare Innovators ETF (BTEC).

What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
What is Intra-Cellular Therapies' stock symbol?: Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
Who are Intra-Cellular Therapies' major shareholders?: Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.45%), BlackRock Inc. (7.58%), Wellington Management Group LLP (5.24%), Wasatch Advisors LP (4.67%), State Street Corp (2.11%) and JPMorgan Chase & Co. (1.91%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intra-Cellular Therapies' stock price today?: One share of ITCI stock can currently be purchased for approximately $63.21.
How much money does Intra-Cellular Therapies make?: Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $6.06 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.
How many employees does Intra-Cellular Therapies have?: The company employs 512 workers across the globe.
How can I contact Intra-Cellular Therapies?: Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial